TTY Biopharm Co Ltd (4105) - Total Liabilities

Latest as of December 2025: NT$3.30 Billion TWD ≈ $103.86 Million USD

Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has total liabilities worth NT$3.30 Billion TWD (≈ $103.86 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

TTY Biopharm Co Ltd - Total Liabilities Trend (2017–2025)

This chart illustrates how TTY Biopharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See TTY Biopharm Co Ltd (4105) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

TTY Biopharm Co Ltd Competitors by Total Liabilities

The table below lists competitors of TTY Biopharm Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
N-Able Inc NYSE:NABL	USA	$596.49 Million
Shenzhen Guangju Energy Co Ltd SHE:000096	China	CN¥546.23 Million
Sparebank 1 Ostfold Akershus OL:SOAG	Norway	Nkr27.30 Billion
Shenzhen King Explorer Science and Technology Corp Class A SHE:002917	China	CN¥1.28 Billion
Oeneo SA PA:SBT	France	€193.53 Million
Luoyang Glass SHG:600876	China	CN¥10.33 Billion
Shanghai Jin Jiang International Industrial Investment Co Ltd A SHG:600650	China	CN¥1.08 Billion
Jinneng Science&Tech Co Ltd SHG:603113	China	CN¥12.42 Billion

Liability Composition Analysis (2017–2025)

This chart breaks down TTY Biopharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of TTY Biopharm Co Ltd.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.28	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.46	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how TTY Biopharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for TTY Biopharm Co Ltd (2017–2025)

The table below shows the annual total liabilities of TTY Biopharm Co Ltd from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$3.30 Billion ≈ $103.86 Million	-1.64%
2024-12-31	NT$3.35 Billion ≈ $105.60 Million	-0.50%
2023-12-31	NT$3.37 Billion ≈ $106.13 Million	+0.04%
2022-12-31	NT$3.37 Billion ≈ $106.09 Million	-4.59%
2021-12-31	NT$3.53 Billion ≈ $111.19 Million	+7.51%
2020-12-31	NT$3.28 Billion ≈ $103.42 Million	-2.98%
2019-12-31	NT$3.38 Billion ≈ $106.60 Million	+27.13%
2018-12-31	NT$2.66 Billion ≈ $83.85 Million	-21.61%
2017-12-31	NT$3.40 Billion ≈ $106.97 Million	--

About TTY Biopharm Co Ltd

TWO:4105 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$575.79 Million

NT$18.28 Billion TWD

Market Cap Rank

#11650 Global

#441 in Taiwan

Share Price

NT$73.50

Change (1 day)

-0.27%

52-Week Range

NT$72.10 - NT$86.30

All Time High

NT$97.91